Immix Biopharma, Inc
Biotechnology - , ,
Immix Biopharma, Inc Employees
Immix Biopharma, Inc Details
Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Immix Biopharma, Inc Technologies
Email Providers
Outlook
Load Balancers
Apache
Fonts
Google Font API
Other
Microsoft Office 365
Hosting
GoDaddy Hosting
CSS and JavaScript Libraries
Amcharts JS Library